Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články
- MeSH
- akrylamidy aplikace a dávkování farmakologie MeSH
- chemorezistence MeSH
- doxorubicin aplikace a dávkování farmakologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- neuroblastom farmakoterapie metabolismus MeSH
- P-glykoprotein antagonisté a inhibitory biosyntéza MeSH
- protokoly protinádorové kombinované chemoterapie farmakologie MeSH
- ritonavir aplikace a dávkování farmakologie MeSH
- screeningové testy protinádorových léčiv MeSH
- synergismus léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- akrylamidy MeSH
- doxorubicin MeSH
- N-(2-hydroxypropyl)methacrylamide MeSH Prohlížeč
- P-glykoprotein MeSH
- ritonavir MeSH
Polymer prodrugs can considerably improve the treatment of tumors with multidrug resistance, often caused by overexpression of P-glycoprotein (P-gp). Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. The increase in cytotoxicity after polymer-RIT conjugate pretreatment was higher for the lines overexpressing P-gp and less pronounced for those with decreased P-gp levels. Moreover, the effect of polymer conjugate containing inhibitor and DOX on the same polymer chain was lower than that of two individual polymer conjugates used sequentially. In conclusion, the polymer-RIT conjugate can significantly increase the cytotoxicity of free DOX and polymer-DOX conjugates in cells with various multidrug resistance origins and can thus be considered a suitable therapeutic enhancer of polymer prodrugs.
Citace poskytuje Crossref.org
